ReviewMicroRNA (Shariqah, United Arab Emirates)2026
Role of Exosomal Non-Coding RNAs
Review in MicroRNA (Shariqah, United Arab Emirates), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal Cancer (CRC) is the third most lethal cancer worldwide. Complex intercellular communication within the tumor microenvironment influences cancer progression, therapeutic resistance, with Exosomes (Exos) and Circulating Extracellular Vesicles (EVs) playing a critical role in this communication. Exosomes can impact recipient cells by carrying various biomolecules, promoting changes that support cancer progression. This review focuses specifically on exosome-derived noncoding RNAs (ncRNAs) in CRC, including microRNAs (miRNAs]), circular RNAs (circRNAs), and long noncoding RNAs (lncRNAs), as significant regulators of cancer biology. The roles of these exosomal ncRNAs in CRC are central to tumor progression, metastasis, and treatment resistance. This review delves into specific molecular mechanisms, such as exosomal lncRNA H19, which enhances CRC chemoresistance by activating the β-catenin pathway, and exo-miR-21, which is implicated in 5-FU chemoresistance. We also highlight emerging evidence on exosomal circRNAs like circ_0006174, linked to doxorubicin resistance through miR-1205/CCND2 axis modulation. These exo-ncRNAs have shown promise as biomarkers and potential therapeutic targets, with studies indicating their diagnostic and prognostic capabilities in CRC patient cohorts. By examining recent in vivo and in vitro studies, we offer a comprehensive understanding of exosomal ncRNAs' roles in CRC pathogenesis and potential applications in clinical trials.
Indexed as
Identifiers
40108898What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.